Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide maintenance versus placebo after first-line therapy in high-risk chronic lymphocytic leukemia
2011-004698-98Phase 3Completed
- Sponsor
- University of Cologne
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Lenalidomide maintenance with Placebo maintenance (2 arms). Primary endpoint: Efficacy of lenalidomide versus placebo maintenance therapy. Started Mar 2012; status: completed.
02
Drugs
lenalidomide
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2011-004698-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004698-98.